Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Not Enough Beds To Go Around To Meet Asia’s Rising Demand For Medical Tourism

This article was originally published in PharmAsia News

Executive Summary

Frost & Sullivan weighs in on the state of medical tourism in southeast Asia, where some countries see greater opportunities for public-private partnerships.

You may also be interested in...



Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings

BEIJING - As leaders in China's central government gathered last week in Beijing to take part in the National People's Congress, they revealed that the price of ever-expanding healthcare reforms, ultimately aimed at providing universal coverage and commonly affordable medical care through measures including the national Essential Drug List, has already risen above RMB 1 trillion

MNCs Urge Indonesia For Exemption From Decree Requiring Local Manufacturing Facilities

Multinational companies are putting pressure on Indonesia's Ministry of Health to exempt them from a new decree requiring foreign drug companies to have local production facilities or leave Indonesia, according to Merck and Sanofi-Aventis

Indonesia Decree Requiring Foreign Drug Makers To Build Local Plants “Disastrous”

PERTH, Australia - A decree issued by Indonesia's health minister earlier this month requiring foreign drug manufacturers to build manufacturing plants in the country, or leave, would be disastrous to the industry, an industry leader said

Topics

Latest News
UsernamePublicRestriction

Register

SC076994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel